Sanofi has agreed a deal to buy US biopharma company Provention Bio for $2.9 billion, taking control of a recently-approved type 1 diabetes (T1D) prevention therapy Tzield
Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been pr
At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-m
US retailer Costco has made a play for a bigger slice of the healthcare market by offering its members online health visits, starting from just $29, as well as other servi
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho